Evidence mapPaperPMID 38466037Full record

ArticleCancer medicine2024

TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.

Karen Lisa Smith, Carolyn Mead-Harvey, Gina L Mazza, Eileen H Shinn, Elizabeth S Frank, Michelle E Melisko, Cyd Eaton, Yisi Liu, Jeannine M Salamone, Teri Pollastro and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Karen Lisa SmithSidney Kimmel Comprehensive Cancer Center, Women's Malignancies Disease Group, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carolyn Mead-HarveyDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA.
Gina L MazzaDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA.
Eileen H ShinnDepartment of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth S FrankDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Michelle E MeliskoDepartment of Medicine (Hematology/Oncology), University of California, San Francisco, California, USA.
Cyd EatonBiostatistics, Epidemiology and Data Management Core, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yisi LiuBiostatistics, Epidemiology and Data Management Core, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jeannine M SalamoneGeorgetown Breast Cancer Advocates, Washington, District of Columbia, USA.
Teri PollastroUniversity of Washington, Seattle, Washington, USA.
Patricia A SpearsLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Nicole E CastonDivision of Hematology and Oncology, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA.ORCID 0000-0001-7474-6110
Antonio C WolffSidney Kimmel Comprehensive Cancer Center, Women's Malignancies Disease Group, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gabrielle Betty RocqueDivision of Hematology and Oncology, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA.ORCID 0000-0003-4188-9785
Johns Hopkins University · USMayo Clinic in Arizona · USUniversity of Alabama at Birmingham · USAdvocates for Youth · USDana-Farber Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer patients experienced heightened anxiety during the pandemic. Also, modifications to clinical trial activities allowing for virtual platforms, local assessments, and greater flexibility were introduced to facilitate participation. We sought to evaluate the association between pandemic-related anxiety and willingness to participate in trials and how pandemic-era modifications to trial activities affect the decision to participate.

methodsWe conducted an online survey from August to September, 2021 of patients with breast cancer assessing pandemic-related anxiety; clinical trials knowledge and attitudes; willingness to participate during and before the pandemic; and how each modification affects the decision to participate. Fisher's exact tests evaluated differences in proportions and two-sample t-tests evaluated differences in means. The association of pandemic-related anxiety with a decline in willingness to participate during compared to prior to the pandemic was modeled using logistic regression.

resultsAmong 385 respondents who completed the survey, 81% reported moderate-severe pandemic-related anxiety. Mean willingness to participate in a trial was lower during the pandemic than prior [2.97 (SD 1.17) vs. 3.10 (SD 1.09), (p < 0.001)]. Severe anxiety was associated with higher odds of diminished willingness to participate during the pandemic compared to prior (OR 5.07). Each of the modifications, with the exception of opting out of research-only blood tests, were endorsed by >50% of respondents as strategies that would increase their likelihood of deciding to participate.

conclusionsWhile pandemic-related anxiety was associated with diminished willingness to participate in trials, the leading reasons for reluctance to consider trial participation were unrelated to the pandemic but included worries about not getting the best treatment, side effects, and delaying care. Patients view trial modifications favorably, supporting continuation of these modifications, as endorsed by the National Cancer Institute and others.

Indexed as

Breast NeoplasmsClinical Trials as TopicPandemicsPatient ParticipationAnxietyFemaleHumansSurveys and Questionnairesbreast cancerclinical trialsCOVID-19pandemicsurvey

Identifiers

PMID38466037
PMCPMC10926883
OpenAlexW4392651250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.